Nanomolar cholera toxin inhibitors based on symmetrical pentavalent ganglioside GM1os-sym-corannulenes by Mattarella, M. et al.
Organic &
Biomolecular Chemistry
PAPER
Cite this: Org. Biomol. Chem., 2013, 11,
4333
Received 3rd March 2013,
Accepted 11th May 2013
DOI: 10.1039/c3ob40438b
www.rsc.org/obc
Nanomolar cholera toxin inhibitors based on
symmetrical pentavalent ganglioside
GM1os-sym-corannulenes†
Martin Mattarella,‡a Jaime Garcia-Hartjes,‡b Tom Wennekes,b Han Zuilhof*b,c and
Jay S. Siegel*a
Eight symmetric and pentavalent corannulene derivatives were functionalized with galactose and the
ganglioside GM1-oligosaccharide (GM1os) via copper-catalyzed alkyne-azide cycloaddition (CuAAC) reac-
tions. The compounds were evaluated for their ability to inhibit the binding of the pentavalent cholera
toxin to its natural ligand, ganglioside GM1. In this assay, all ganglioside GM1os-sym-corannulenes
proved to be highly potent nanomolar inhibitors of cholera toxin.
1. Introduction
The World Health Organization (WHO) estimates that annually
3–5 million people worldwide are infected with cholera, result-
ing in over a hundred thousand fatalities.1 The responsible
pathogen, the Vibrio cholerae bacterium, produces the cholera
toxin (CT) protein that is responsible for the severe clinical
symptoms. CT belongs to the protein family of AB5 bacterial
toxins.2 The structure and activity of CT and other AB5 toxins
have been investigated in detail.3 These proteins consist of two
distinct domains with diﬀerent roles. The A-subunit is an
enzyme that – when delivered inside a host cell – is toxic and
responsible for the subsequent disease symptoms. The cholera
toxin B-subunit (CTB) is a lectin and plays a crucial role in the
recognition and interaction with its natural ligand, ganglioside
GM1 (Fig. 1a), on the periphery of intestinal cells. The crystal
structure of CT4 shows that the protein complex consists of
five identical monomeric CTB subunits, arranged in a penta-
gonal symmetry, and each of these subunits can bind the
ganglioside GM1 in a one-to-one stoichiometry. Detailed
calorimetric studies revealed that CT exhibits allosteric co-
operativity,5 which contributes to increasingly higher binding
aﬃnities to CT when more ligands are bound.6
One of the possible approaches for the design of CT inhibi-
tors aims to prevent the receptor-recognition process.7 Two
major routes can be discerned in the literature to achieve this
goal. The first strategy, monovalent receptor-binding approach,
focuses on strong binding interactions, and it is based on the
design and synthesis of ligands that closely mimic the natural
ligand on the cell surface8 in order to obtain a strong inter-
action with the CTB receptor. The second approach, multi-
valent receptor-binding,9 exploiting chelate cooperativity, takes
advantage of the pentavalent character of the ligand-binding
sites of CT. This approach is based on the synthesis of a func-
tionalized branched system, in which each branch carries a
single-site inhibitor, like galactose10,11 or lactose,12 leading to
a compound that has an overall stronger interaction with the
toxin than the sum of the independent inhibitors. The syn-
thesis of dendritic multivalent inhibitors, functionalized with
the GM1os, has been reported;13 these displayed unprece-
dented high inhibitory potencies for CTB, in the picomolar
range.
An important improvement in the design of multivalent
binders was achieved with symmetrical pentameric molecules
based on the concept of “finger-linker-core” systems:12 the
pentavalent “core” is connected by flexible “linkers” to
“fingers” that include the monovalent receptor-binding ligand.
Pentavalent CT inhibitors were synthesized using various
“cores”: acylated pentacyclen,12a a large cyclic peptide12e and
calix[5]arene.14
This paper details a study that combines the two strategies
to obtain an optimal binding by the design and synthesis of
pentavalent GM1os-presenting compounds based on a 5-fold
symmetrical sym-substituted15 corannulene scaﬀold (Fig. 1b).
Binding assays allowed the determination of the interaction
with CT-B5 (the protein complex without the toxic A part) for
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these and analogous pentavalent galactose corannulenes. This
revealed a high inhibitory potency towards CTB by this new
class of inhibitors.
2. Results and discussion
Apart from its obvious 5-fold symmetry, the corannulene
scaﬀold is a good candidate to function as the “core” of penta-
valent receptor-binding inhibitors for AB5 toxins on the basis
of the following observations: the recent development of a
kilogram-scale synthesis of corannulene (1),16 its further
functionalization to sym-pentachloro-corannulene (2),17 and
the growing number of robust and flexible procedures for the
preparation of molecular pentapods displaying functional
groups and bioconjugated moieties, by iron-catalyzed18 cross-
coupling and copper-catalyzed azide-alkyne cycloaddition
(CuAAC) reaction.
The synthetic pathway towards PEG-corannulene systems
starts from the conjugation of the terminal acetylene 318 by an
eﬃcient copper nanoparticle-catalyzed CuAAC reaction with
n-mers of α-azidoethyl-ω-propargyl diglyme (n = 1, 2, 4) (Fig. S1
in the ESI†).19 This route gave satisfactory results for the prepa-
ration of other sym-bioconjugated corannulenes, and was used
here to prepare the five-fold symmetric compounds 5, 6 and 7
in good yield and purity. The PEG arms function as linkers of
diﬀerent lengths and improve water solubility and flexibility of
the inhibitor. The terminal TIPS-protected acetylenes were
deprotected by reaction with TBAF19 yielding the alkyne-termi-
nated PEG-corannulenes 8, 9 and 10 (Scheme 1).
After preparing the three PEG-corannulenes the focus
shifted to attaching the (oligo)saccharides. In this work, two
diﬀerent CTB binders were used: galactose, an easily obtain-
able but quite poor binder of CTB, and the oligosaccharide of
ganglioside GM1 (GM1os), the natural ligand of CTB.
In order to introduce the galactose-based “finger” to the
terminal acetylenes 3, 8, 9 and 10, galactoside 11 was functio-
nalized at the anomeric position with a short PEG chain that
bears an azido group (compound 12, Scheme 2). An analogous
compound without ethylene oxide moieties belonging to this
inhibitor family was previously synthesized18 by CuAAC reac-
tion on the terminal acetylene 3 and 2-azidoethyl-β-D-galacto-
pyranoside.20,21 The synthetic pathway for the synthesis of
azido-PEG-galactoside 14 starts with a Koenigs–Knorr-type gly-
cosylation of azido-PEG hydroxide 1222,23 with peracetylated
galactosyl bromide 11 to aﬀord β-galactoside 13. The depro-
tected compound 14 was then obtained by treatment of 13
with sodium methoxide. The pentavalent Gal-functionalized
sym-corannulene inhibitor was prepared in good yield by
employing the microwave-assisted CuAAC reaction on the
Fig. 1 (a) Structure of CTB’s natural ligand, ganglioside GM1; (b) structure of the pentavalent GM1os-functionalized sym-corannulene, a nanomolar inhibitor of
cholera toxin.
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terminal acetylenes 3, 8, 9 and 10 with the azido galactose
derivative 14 aﬀording the four galactose-based CTB inhibitors
15–18 (Scheme 3).
The second family of pentavalent inhibitors displays five
GM1os moieties (Scheme 4). The chemo-enzymatic synthesis
from lactose of the azide-terminated GM1os oligosaccharide
was previously reported.24 The pentavalent GM1os inhibitors
20, 21 and 22 were synthesized, in the presence of copper
nanoparticles, by microwave-assisted CuAAC reaction of azido-
pentasaccharide 19 with the terminal acetylenes 8, 9 and 10.
Because of the low solubility of the GM1 analog in DMF, the
reactions were performed in water, allowing a complete dis-
solution of 19 in the reaction media.
The inhibitory eﬃciency of the synthesized five-fold sym-
metric pentavalent CT ligands (15–18 and 20–22) was evalu-
ated by an ELISA-type assay on 96-well plates.25,26 Solubility
issues at concentrations >1 mM limited the experiments
intended to find an IC50-value for galactose-based compounds
Scheme 1 Synthesis route of the corannulene core and ethylene glycol spacers. (i) ICl, DCM, r.t., 72 h; (ii) 1. Fe(acac)3, 1-bromo-4-trimethylsilyl-3-butyne, THF–NMP,
r.t., 2.5 h; 2. NaOH, MeOH–H2O, r.t., 24 h; (iii) Cu nanoparticles, DMF, microwave, 60 °C, 2 h; (iv) TBAF, THF, r.t., 2 h.
Scheme 2 Synthesis of azido-linked galactoside 14. (i) HgBr2, DCM, r.t., 3 d; (ii) (1) MeONa, MeOH, r.t., 48 h; (2) DOWEX-H
+.
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15–18. When compared to previously reported IC50-values for
multivalent ligands functionalized with galactose,10,11 these
concentrations should not have been limiting. One hypothesis
to account for this observation is that the supramolecular
aggregation competes against binding to the pentad-complex.
Further investigations by 1H-NMR, UV-Vis and fluorescence
spectroscopy on the properties of C5-symmetric galactose con-
jugated corannulene in aqueous solution suggest the for-
mation of supramolecular aggregates of this amphiphilic
molecule in water. If the formation of the supramolecular
Scheme 3 Microwave-assisted CuAAC-based synthesis of penta-galactose corannulenes. (i) 14, Cu nanoparticles, DMF, microwave, 80 °C, 2 h.
Scheme 4 Synthesis of the GM1os-functionalized PEG-corannulenes. (i) Cu nanoparticles, H2O, microwave, 80 °C, 2 h.
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assemblies is thermodynamically and kinetically favored over
the interaction with the CTB, the competition of these two pro-
cesses might be a plausible explanation for the unexpected
results obtained from the ELISA assays; however, the GM1os-
PEG-corannulenes showed high, nanomolar inhibitory poten-
cies (Fig. 2; Table 1).
The pentavalent GM1os-functionalized inhibitors, 20, 21,
and 22, bind CTB at lower IC50 values than monomeric GM1os
(cf. Table 1). The lowest IC50-value measured is for 21 (Table 1,
entry 2) with an inhibition potency that is nearly 4000 times
stronger than that of monomeric GM1os.12f The lower binding
aﬃnity for CTB by compounds 20 and 22 (Table 1, entries 1
and 3) is most probably due to the eﬀects related to the linker
length: if the linker is not long enough (compound 20), not all
of the five ligands can simultaneously bind the five binding
sites of CTB. In the opposite case (i.e. compound 22), binding
would lead to a substantial ordering in the chain, making it
entropically less favorable, while enthalpically the necessary
folding of the longer linkers to enable binding of CTB by the
GM1os fingers might create suﬃcient steric hindrance to
cause an increased IC50-value. A further complicating factor is
the possibility that galactose and GM1os derivatives undergo
supramolecular self-aggregation that competes with binding to
CTB and results in apparent higher inhibitory concentrations.
Caveats notwithstanding, 21 is as of yet one of the strongest
multivalent CT inhibitors,22,27 and displays the power of
combining the natural valency with the natural ganglioside to
reach optimal blocking of multivalent lectins. Design eﬀorts to
create systems that optimize spacer geometry and avoid self
complexation will likely lead to new derivatives with inhibitory
concentrations more favorably comparable to other previously
reported GM1os-based inhibitors.
3. Conclusions
This manuscript reports a powerful method for the synthesis
of a new class of cholera toxin inhibitors with a design based
on a pentavalent sym-substituted corannulene as the core unit
and equipped with the galactose and the GM1os as CTB
binders. Microwave-assisted CuAAC reactions, catalyzed by
copper nanoparticles, were employed for the conjugation of
the monovalent CTB ligands (galactose and GM1os) to the cor-
annulene core via azide-presenting PEG-linkers of various
lengths. The potent CTB inhibition of 25, 5.0, and 7.3 nM
observed for the penta-GM1os corannulenes, 20, 21, and 22,
respectively, prove that multivalent systems functionalized
with strong CTB binders represent a solid strategic approach
for the synthesis of CT inhibitors with high potency in com-
parison with previously reported monovalent inhibitors.
The developed method allows for the use of sym-substituted
corannulenes as a possible core unit for the development of
new multivalent binders of cholera toxin or other possible bio-
logical targets that rely on multivalent binding of their target
ligand.
4. Representative experimental procedures
Compound 6
A mixture of 3 (9.4 mg, 18 μmol), the proper azide-functiona-
lized PEG (83.0 mg, 0.14 mmol) and copper nanoparticles
(11.7 mg, 0.18 mmol) in DMF (1.0 mL) was loaded in a micro-
wave vessel and was heated at 80 °C in a microwave reactor for
2 h. The reaction mixture was filtrated over celite and the
solvent evaporated. The crude mixture was purified by column
chromatography on silica gel (from DCM–MeOH 94 : 6 to
DCM–MeOH 9 : 1) to yield a reddish oil (49 mg, 79%). 1H-NMR
(500 MHz, CDCl3): δ 7.69 (s, 5H), 7.64 (s, 5H), 7.53 (s, 5H), 4.62
(s, 10H), 4.48 (q, J = 5.5 Hz, 20 H), 4.21 (s, 10H), 3.82 (t, J =
5.0 Hz, 20H), 3.69–3.47 (m, 90H), 3.26 (t, J = 8.0 Hz, 10H), 1.04 (s,
105H). 13C-NMR (125 MHz, CDCl3): δ 147.07, 144.81, 140.42,
134.88, 129.74, 123.91, 123.06, 122.47, 103.21, 87.81, 70.55,
70.54 70.51, 70.47, 69.68, 69.64, 69.52, 68.72, 64.58, 59.28,
50.32, 50.27, 33.38, 28.49, 18.66, 11.20. HRMS (ESI) m/z: found
1163.6590 (M + 3Na); calc. (C175H280N30Na3O30Si5) 1163.6609.
Compound 9
A solution of TBAF in THF (1 M, 1.0 mL, 1.0 mmol) was added
to a solution of 6 (103 mg, 30.1 μmol) in THF (1.0 mL) and the
reaction mixture was stirred at r.t. for 2 h. The solution was
then diluted with a saturated aqueous solution of NH4Cl and
Fig. 2 Fitted inhibition curves of compounds GM1os-PEG3 corannulene 20
(purple line), GM1os-PEG6 corannulene 21 (red line), and GM1os-PEG12 cor-
annulene 22 (green line).
Table 1 Inhibitory potency of pentavalent GM1os-functionalized ligands
towards CTB
Entry Compound IC50 (nM) RIP
a
1 20 25 ± 4 770
2 21 5 ± 2 3700
3 22 7.3 ± 0.9 2600
a RIP = relative inhibition potency calculated as the ratio between the
IC50 value of the inhibitor and the IC50 value of GM1os (ref. 12f ).
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extracted with ethyl acetate. The collected organic phases were
dried over NasSO4 and evaporated to yield the crude product.
The crude was then heated at 75 °C under high vacuum for
18 h. The product was then purified by column chromato-
graphy on silica gel (DCM–MeOH 9 : 1) to yield a reddish oil
(24 mg, 30%). 1H-NMR (500 MHz, CDCl3):
1H-NMR (500 MHz,
CDCl3): δ 7.70 (s, 5H), 7.64 (s, 5H), 7.53 (s, 5H), 4.62 (s, 10H),
4.50–4.46 (m, 20 H), 4.16 (d, J = 2.5 Hz, 10H), 3.82 (t, J =
5.0 Hz, 20H), 3.64–3.51 (m, 90H), 3.23 (t, J = 8.0 Hz, 10H), 2.44 (d,
J = 2.5 Hz, 5H). 13C-NMR (125 MHz, CDCl3): δ 147.11, 144.83,
140.47, 134.89, 129.76, 123.97, 123.07, 122.47, 79.70, 74.86,
70.57, 70.55, 70.47, 69.65, 69.52, 69.14, 64.72, 58.48, 50.26,
50.20, 33.39, 28.52. HRMS (ESI) m/z: found 529.2767 (M + 5H);
calc. (C130H185N30O30) 529.2769.
Compound 17
A mixture of 9 (8.5 mg, 3.2 μmol), 14 (11.3 mg, 24.1 μmol) and
copper nanoparticles (1.5 mg, 23.6 μmol) in DMF (300 μL) was
loaded into a microwave vessel and was heated at 80 °C in a
microwave reactor for 2 h. The mixture was filtrated over celite
and the solid was washed with water. The crude was lyophi-
lized and purified by size exclusion chromatography (Sepha-
dex® G-25, water) to yield a reddish solid (9.1 mg, 57%).
1H-NMR (500 MHz, D2O/d
4-MeOD): δ 8.01 (s, 5H), 7.88 (s, 5H),
7.68 (s, 5H), 7.60 (s, 5H), 4.58–4.39 (m, 50H), 4.08–4.06 (m,
5H), 3.98–3.12 (m, 255H). 13C-NMR (125 MHz, D2O/d
4-MeOD):
δ 147.90, 144.84, 141.31, 134.78, 130.36, 126.25, 126.05, 124.76
124.23, 103.86, 76.12, 73.69, 71.73, 70.69, 70.57, 70.52, 70.42,
70.41, 70.35, 70.27, 70.24, 69.86, 69.79, 69.73, 69.65, 69.61,
69.54, 63.99, 61.93, 50.90, 50.77, 49.52, 33.97, 28.11. HRMS
(ESI) m/z: found 854.2378 (M + 6Na); calc. (C220H355N45Na6O85)
854.2366.
Compound 21
A mixture of 9 (2.88 mg, 1.09 μmol), 19 (11.1 mg, 9.3 μmol)
and copper nanoparticles (0.76 mg, 12.0 μmol) in water
(300 μL) was loaded into a microwave vessel and was heated at
80 °C in a microwave reactor for 2 h. The mixture was filtrated
over celite and the solid was washed with water. The crude was
lyophilized and purified by size exclusion chromatography
(Sephadex® G-25, water) to yield a colorless solid (4.8 mg,
51%). 1H-NMR (500 MHz, D2O/d
4-MeOD): δ 7.96–7.75 (m,
20H), 4.57–4.54 (m, 70H), 4.18–4.05 (m, 45H), 3.94–3.34 (m,
286H), 2.70 (d, J = 10.0 Hz, 5H), 2.06 (d, J = 15.0 Hz, 35H),
1.98–1.94 (t, J = 10.0 Hz, 5H), 1.62–1.45 (m br, 25H), 1.28–1.25
(m br, 20H), 1.11–0.90 (m br, 75H). 13C-NMR (125 MHz, D2O/
d4-MeOD): δ 175.96, 175.06, 105.70, 103.61, 103.48, 103.18,
102.70, 75.83, 75.32, 73.47, 71.66, 70.66, 70.64, 70.62, 70.52,
70.50, 70.48, 70.47, 70.45, 69.59, 69.57, 61.90, 52.61, 52.12,
51.13, 51.11, 29.73, 26.58, 26.23, 23.58, 22.99. HRMS (ESI) m/z:
found 1721.1778 (M − 5H); calc. (C370H590N55O175) 1720.7797.
ELISA assays
Each well of a 96-well microtiter plate was coated with a 100 μL
native GM1 solution (1.3 μM in ethanol) after which the
solvent was evaporated. Unattached GM1 was removed by
washing with PBS (3 × 450 μL), and the remaining free binding
sites were blocked by incubation with 100 μL of a 1% (w/v) BSA
solution in PBS for 30 min at 37 °C. Subsequently, the wells
were washed with PBS (3 × 450 μL). In separate vials, a logarith-
mic serial dilution, starting from 2.0 mM, of 150 μL sacchar-
ide-corannulenes in 0.1% BSA, 0.05% Tween-20 in PBS, mixed
with 150 μL of a 50 ng mL−1 CTB–HRP solution in the same
buﬀer, were incubated. This gave an initial inhibitor concen-
tration of 1.0 mM. In the case of potent inhibitors, based on
the logarithmic experiments, a more accurate, serial dilution
of a factor of two was performed around the expected IC50
values. The inhibitor-toxin mixtures were incubated at room
temperature for 2 h and then transferred to the coated wells.
After 30 min of incubation at room temperature, unbound
CTB–HRP–corannulene complexes were removed from the
wells by washing with 0.1% BSA, 0.05% Tween-20 in PBS (3 ×
500 μL). 100 μL of a freshly prepared OPD solution (25 mg
OPD·2HCl, 7.5 mL 0.1 M citric acid, 7.5 mL 0.1 M sodium
citrate and 6 μL of a 30% H2O2 solution, pH was adjusted to
6.0 with NaOH) was added to each well and allowed to react
with HRP in the absence of light, at room temperature, for
15 min. The oxidation reaction was quenched by the addition
of 50 μL 1 M H2SO4. Within 5 min, the adsorbance was
measured at 490 nm.
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